Innate Pharma S.A. (IPHA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Innate Pharma S.A. (IPHA) closed at USD 1.43 on 2026-10-14, a change of -31.6 % over the past year, with a market capitalization of USD 165.32M.

Innate Pharma S.A. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Innate Pharma S.A. key figures

Previous close

USD 1.43 (2026-10-14)

1-year change

-31.6 %

Market cap

USD 165.32M

Enterprise value

USD 147.99M

P/E ratio (trailing)

-2.51

P/E ratio (forward)

-3.14

EPS (trailing)

-0.59

EPS (forward)

-0.47

PEG ratio

n/a

Price to book

-3.04

Revenue growth

16.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.92

Employees

120

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Innate Pharma S.A.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Innate Pharma S.A. and compare it with other stocks.